Naj Sharif, PhD, FARVO, FBPhS was educated and trained in England at Southampton University (BSc (Joint Honors: Biochemistry and Physiology); PhD (Neuroscience)). His pharmaceutical industry experience (>32 years) includes holding leadership positions in discovery research, drug development and regulatory affairs at Pfizer, Syntex (Roche), Alcon-Novartis and Santen. His 22-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Simbrinza®, and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies. At Santen he has contributed towards the in-licensing and acquisition of InnFocus Microshunt, and to various drug candidates. He is a Fellow of ARVO (FARVO), and of British Pharmacological Society (FBPhS). Dr. Sharif received the inaugural Dr. Roger Vogel Award for ocular pharmaceutical research, and the “Sir James Black Award” for contributions to drug discovery. He serves on the editorial boards of numerous journals, and is an Adjunct Professor at several Universities. He has published >210 papers, edited 2 books, and is the holder of 23 issued patents.
Drug Discovery & Development
Gus R. Rosania is a Professor of Pharmceutical Sciences at the University of Michigan College of Pharmacy. Here, he leads a research group studying the transport mechanisms responsible for the disposition of small molecule drugs from the whole organism to the subcellular level. His research group has taken a special interest in studying poorly soluble drugs with very large volumes of distribution. His investigations combine physical, chemical, biological and computational studies with the ultimate goal of repurposing drugs by developing novel formulations for site directed drug targeting and delivery.